50 employees
Lexent Bio is building novel liquid biopsy technology to change the way we diagnose and treat cancer.
2016
Lexent Bio raised undisclosed on January 1, 2018
Investors: Charge Ventures
Lexent Bio raised undisclosed on December 1, 2016
Investors: iFly.vc